Small interfering RNA encapsulated nanocells - EnGeneIC

Drug Profile

Small interfering RNA encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVPLK; EGFREDVRRM1

Latest Information Update: 30 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EnGeneIC
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adrenocortical carcinoma; Solid tumours

Most Recent Events

  • 29 Sep 2017 Phase-I clinical trials in Adrenocortical carcinoma (Late-stage disease) in Australia (IV) (EnGeneIC website, September 2017)
  • 12 Aug 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top